Lyon has long played a vital role in global health and today stands as one of Europe’s most investable life sciences hubs. While less well-known than Basel, Barcelona, London, or Paris, Lyon stands out through its tight-knit ecosystem of hospitals, research institutes, pharma and medtech manufacturers, biotechs, and service providers. The density and breadth of…
InFocus
The global landscape for genomic medicine reached an inflection point in late 2025. First-in-human data confirmed that in vivo CAR-T – once a theoretical ambition – is now a biological reality, capable of extraordinary efficacy in patients with hard-to-treat autoimmune diseases. As this exclusive new Selesta* report shows, China has secured a commanding global lead…
This report is the first in PharmaBoardroom’s InFocus: China Biotech Catalysts series, profiling the companies and leaders shaping the next wave of global biotech innovation. PharmaBoardroom has been at the forefront of China’s biopharma boom for almost 20 years, speaking to founders, pharmas and VCs on the ground and doing more than almost any other…
Hong Kong is rapidly transforming from a regional observer into an active force in cell and gene therapy. Long known as a bridge between China and the world, the city is already delivering “Made in Hong Kong” CAR-T therapies under clinical trial conditions and boasts Asia’s first university-led GMP-certified CGT manufacturing centre. With the enticing…
Tremendous scientific and social progress has transformed HIV/AIDS from a death sentence to a manageable chronic condition for many. However, the disease still kills 650,000 people every year with formidable societal, legal, and economic obstacles remaining to realising the ultimate quest of complete eradication. This dedicated InFocus, bringing together key stakeholders in the global HIV…
2023 was a year of transformative change and challenge across the global healthcare and life sciences industries. Drawing on PharmaBoardroom’s exclusive interviews and op-eds from across the world in 2023, our latest report tackles some of the year’s key regional trends. It includes everything from the landmark introduction of drug price negotiations in the US…
With the tremendous healthcare momentum that is already underway in the Gulf Cooperation Council (GCC) countries, driven by economic diversification and transformation, the future of healthcare in the region looks bright. Government initiatives such as Saudi Arabia’s Health Sector Transformation Program, a vital component of the country’s economic and social reform roadmap, Vision 2030, coupled…
The global market for biosimilars has soared in recent years, driven by a push from healthcare systems across the world to take advantage of the savings that these products have to offer. This market stood at over USD 15 billion in 2020, having grown at a CAGR of 56 percent since 2015. Moreover, McKinsey estimates…
Home to the pharmaceutical heavyweights, Novartis and Roche, elite contract manufacturers and a dizzying array of acclaimed research institutions and medical institutes, Switzerland has long stood proud as a true powerhouse in medical discovery, drug development, and pharma manufacturing. Famed as an early-adopter market with capabilities spanning the entire life science value chain and ever…
Asia is at the forefront of new trends in precision medicine, from pioneering work in molecular diagnostics to increasingly tailored solutions in the war against cancer and in-depth genomic data sets better representing the profiles and needs of the region’s population. This second edition of InFocus Precision Medicine in Asia features insights from some of…
Long dismissed as the backwaters of healthcare innovation, the tremendous value of vaccines – the single most cost-effective health intervention after clean water – made itself starkly clear in 2020, as the discovery of a novel coronavirus quickly exploded into a full-blown global pandemic that rages on still. While billions have since been poured into…
In our second edition of InFocus Five Biotechs to Watch in China, we profile five biotech companies that have all found their own differing routes to success. While it is always tricky to define the starting point of a revolution, the Chinese biopharma boom – whether one considers the genesis to be the government’s public…
